Please login to the form below

Not currently logged in
Email:
Password:

CAR-T

This page shows the latest CAR-T news and features for those working in and with pharma, biotech and healthcare.

Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts

Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts

The company has a portfolio of 16 pre-clinical CAR T cell therapy targets, which it calls AlloCARs. ... Allogene believes its platform will overcome problems seen in other off-the-shelf CAR-T pipelines, and will have the ability to scale production to

Latest news

  • Gilead strikes deal with NHS England on CAR-T Yescarta

    Gilead strikes deal with NHS England on CAR-T Yescarta. NHS England claims adult leukaemia access is first in Europe. ... It is likely that we are only beginning to see the benefits that CAR-T therapy can bring.

  • Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness

    treatment. However today England’s cost effectiveness watchdog NICE has issued a draft ruling that the CAR-T therapy cannot be recommended because it is not cost effective in diffuse large ... This is far from surprising – NICE has already come to

  • Gilead optimistic about Yescarta deal in UK Gilead optimistic about Yescarta deal in UK

    Gilead optimistic about Yescarta deal in UK. Says NICE and NHS England understand groundbreaking nature of CAR-T. ... The CAR-T production process. DLBCL will be the competitive battleground for Novartis and Gilead, and there’s no doubt Yescarta has

  • Health secretary’s ‘rip off’ remarks anger UK pharma Health secretary’s ‘rip off’ remarks anger UK pharma

    months. The most notable of those was the announcement last week that Novartis’groundbreaking CAR-T treatment Kymriah would be available on the NHS for children with acute lymphoblastic leukaemia (ALL). ... wouldn't be drawn on the minister's

  • Novartis’ CAR-T Kymriah gets green light in England Novartis’ CAR-T Kymriah gets green light in England

    Novartis’ CAR-T Kymriah gets green light in England. Speedy decision contrasts with NICE's 'no' to rival Yescarta in larger adult DLBCL population. ... Novartis has set a “fair and affordable”price for its CAR-T therapy Kymriah that should make it

More from news
Approximately 28 fully matching, plus 77 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... The CAR-Ts have transformed the treatment

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    Bluebird Bio's chief executive Nick Leschly. Cell and gene therapy made the transition from an interesting but unproven science to medical reality in 2017, with two ‘living medicine’CAR-T ... Analysts think bb2121 could gain approval by 2020 and hit

  • No incentive for a cure No incentive for a cure

    These include Kymriah, the pioneering CAR-T cell therapy from Novartis, which demonstrated a remarkable 83% remission rate in children and young adults with B-cell precursor acute lymphoblastic leukaemia. ... We won’t know for many years if the

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    But we don’t need any more pilots; the concept has been proven.”. ... CAR-T cell therapy for children with B-cell ALL.

  • The rise of real-world evidence The rise of real-world evidence

    Novartis secured such an outcome-based model for its CAR-T therapy Kymriah.

More from intelligence
Approximately 0 fully matching, plus 34 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Training the next generation of biotech leaders

    In this year alone, the FDA has taken the groundbreaking step of approving two CAR-T therapies. ... In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’ s Yescarta in October.

  • Addressing the biggest challenges for rare disease communities

    It is common that primary care physicians either do not recognise specific symptoms or don’ t make the link between common symptoms and a rare disease. ... And just last year, we saw landmark breakthroughs in advanced genetic therapies, such as viral

  • How do you define a biotech company?

    This approach is particularly apparent in some of the recent examples of technology pioneered by biotech organisations, such as CAR-T technology (Novartis, Juno and Kite Pharma) and RNAi (Alnylam) where  ... However, we can’ t say that this is a trait

  • Addressing the biggest challenges for rare disease communities

    It is common that primary care physicians either do not recognise specific symptoms or don’ t make the link between common symptoms and a rare disease. ... And just last year, we saw landmark breakthroughs in advanced genetic therapies, such as viral

  • Innovation in pharma: the highs and lows of the current healthcare economy

    Also in cancers: chimeric antigen receptor T cell (CAR-T) therapy, a type of cancer immunology that could dismiss chemotherapy in some cancers, is now licensed in the US.

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...

Infographics